AI in Pharma Faces Reality: Intelligence Isn't the Only Bottleneck
anshulkundaje · x · 2026-07-28
Several tech and bio observers are reflecting on the overpromises of the 'AI×Bio' industry. Many companies have raised billions based on the grand narrative of 'running AI on all scientific literature and multi-omics data to cure all diseases in 10 years,' severely underestimating the actual hurdles of drug development.
Key Points:
- Intelligence ≠ Omnipotence: People in AI labs often assure others that AGI will automatically solve regulatory barriers to medical innovation. While models will get smarter, intelligence is often not the main bottleneck for physical world change.
- The Regulatory Chasm: Medical innovation faces complex real-world regulatory and biological validation challenges. Simply throwing computing power and intelligence at them cannot directly bridge these physical and institutional gaps.
More from AGI Musings
- Dario Amodei warns advanced AI could give authoritarian states lasting military superiority — RichmanRonald · 2026-07-29
- Full-duplex voice assistants with life-wide context could replace many phone tasks — willccbb · 2026-07-29
- AI comparisons are rigged, and jobs may be the real casualty — RexDouglass · 2026-07-29
- OpenAI Hack Fueling a New Fight Over Open-Source vs Closed-Source AI — timemagazine · 2026-07-29
- A Reddit post sketches a three-stage future where AI moves from tool to guide — ThomasRuleTalks · 2026-07-29
- User modeling discussion argues personalization should go beyond surface style — EchoShao8899 · 2026-07-29